Soros Capital Management LLC Takes Position in Danaher Co. (NYSE:DHR)

by · The Cerbat Gem

Soros Capital Management LLC bought a new stake in shares of Danaher Co. (NYSE:DHR – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,837 shares of the conglomerate’s stock, valued at approximately $5,793,000. Danaher comprises about 1.4% of Soros Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding.

Several other large investors have also recently made changes to their positions in the business. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the 2nd quarter worth $25,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the 3rd quarter worth $40,000. MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter worth $51,000. Finally, Financial Connections Group Inc. bought a new position in shares of Danaher during the 2nd quarter worth $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $236.53 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average is $256.66 and its 200 day moving average is $259.81. The stock has a market cap of $170.84 billion, a price-to-earnings ratio of 45.14, a P/E/G ratio of 4.37 and a beta of 0.85. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group cut their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Stephens restated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 18th. Finally, Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Check Out Our Latest Analysis on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).